- Home
- OPAD vs PRLD Comparison
OPAD vs PRLD Comparison
Compare OPAD & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- PRLD
- Stock Information
- Founded
- OPAD 2015
- PRLD 2016
- Country
- OPAD United States
- PRLD United States
- Employees
- OPAD N/A
- PRLD N/A
- Industry
- OPAD Real Estate
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- OPAD Finance
- PRLD Health Care
- Exchange
- OPAD Nasdaq
- PRLD Nasdaq
- Market Cap
- OPAD 70.1M
- PRLD 73.7M
- IPO Year
- OPAD N/A
- PRLD 2020
- Fundamental
- Price
- OPAD $1.71
- PRLD $0.66
- Analyst Decision
- OPAD Hold
- PRLD Strong Buy
- Analyst Count
- OPAD 5
- PRLD 2
- Target Price
- OPAD $3.25
- PRLD $4.50
- AVG Volume (30 Days)
- OPAD 85.3K
- PRLD 159.2K
- Earning Date
- OPAD 05-05-2025
- PRLD 03-10-2025
- Dividend Yield
- OPAD N/A
- PRLD N/A
- EPS Growth
- OPAD N/A
- PRLD N/A
- EPS
- OPAD N/A
- PRLD N/A
- Revenue
- OPAD $918,819,000.00
- PRLD $7,000,000.00
- Revenue This Year
- OPAD $8.29
- PRLD N/A
- Revenue Next Year
- OPAD $33.17
- PRLD N/A
- P/E Ratio
- OPAD N/A
- PRLD N/A
- Revenue Growth
- OPAD N/A
- PRLD N/A
- 52 Week Low
- OPAD $1.64
- PRLD $0.66
- 52 Week High
- OPAD $8.79
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- OPAD 34.34
- PRLD 32.13
- Support Level
- OPAD $1.64
- PRLD $0.67
- Resistance Level
- OPAD $2.09
- PRLD $0.77
- Average True Range (ATR)
- OPAD 0.20
- PRLD 0.08
- MACD
- OPAD -0.01
- PRLD -0.01
- Stochastic Oscillator
- OPAD 8.28
- PRLD 0.34
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.